SciBase recalculates TO 2 warrants after rights issue

SciBase has recalculated the terms for its TO 2 series warrants, which were issued in connection with a capital raise announced in April 2024. This recalculation aligns with the conditions set for these warrants.

The adjustment impacts the number of shares that each warrant allows the holder to subscribe for, as well as the subscription price. SciBase has provided detailed information regarding these changes on its corporate website.

The warrants were originally issued as part of the company's capital raising efforts, aimed at strengthening its financial position and supporting business development. Adjustments to warrant terms are standard practice following significant corporate actions like rights issues, ensuring fair value and terms for option holders relative to the new share structure.

This information is relevant for current warrant holders as it details the revised terms for exercising their options. SciBase operates in the medical technology sector, specializing in the diagnostics of skin cancer.